An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study

Home, Philip; Naggar, Nabil El; Hosseinkhan, Nazanin; González-Gálvez, Guillermo; Shen, Chunduo; Chakkarwar, Praful; Yang, Wenying

doi:10.1016/j.diabres.2011.10.021

Cited by 141 publications

(181 citation statements)

References 27 publications

Supporting

Mentioning

162

Contrasting

Unclassified

Order By: Relevance

“…This result is in concordance with the findings in randomized clinical trials [2,5,14,23]. The neutral effect of glargine on body weight in this study may be due to increased self-care behaviors, improvement in lifestyle and nutritional status of the participants [24] suggesting that insulin glargine may be more beneficial in treating obese patients with T2DM [25]. Treatment with insulin glargine leads to a reduction of HbA1c to 7.62% after 24 weeks of treatment.…”

Section: Discussionsupporting

confidence: 82%

Practical Focus on American Diabetes Association/European Association for the Study of Diabetes Consensus Algorithm in Patients with Type 2 Diabetes Mellitus: Timely Insulin Initiation and Titration (Iran-AFECT)

et al. 2017

View full text Add to dashboard Cite

Background:The aim of this study was to evaluate the safety and effectiveness of insulin glargine in a large population from a variety of clinical care in Iranian people with type 2 diabetes mellitus (T2DM) and to measure the percentage of patients achieving glycosylated hemoglobin (HbA1c) <7% by the end of 24 weeks of treatment in routine clinical practice. Methods: This study was a 24 week, observational study of patients with T2DM, for whom the physician had decided to initiate or to switch to insulin glargine. The safety and efficacy of glargine were assessed at baseline and at week 24. Results: Seven hundred and twenty-five people with T2DM (63% female) including both insulin naïve and prior insulin users were recruited in this study. The mean age of the participants was 54.2±11.2 years, and the mean HbA1c level was 8.88%±0.93% at baseline. By the end of the study, 27% of the entire participants reached to HbA1c target of less than 7% and 52% had HbA1c ≤7.5%. No serious adverse event was reported in this study. Furthermore, overall hypoglycemia did not increase in prior insulin users and the entire cohort. In addition, body weight did not change in participants while lipid profile improved significantly. Conclusion: Treatment with insulin glargine could improve glycemic control without increasing the risk of hypoglycemic events in people with T2DM. In addition, a significant clinical improvement was observed in lipid profile.

show abstract

Section: Discussionsupporting

confidence: 82%

Practical Focus on American Diabetes Association/European Association for the Study of Diabetes Consensus Algorithm in Patients with Type 2 Diabetes Mellitus: Timely Insulin Initiation and Titration (Iran-AFECT)

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Furthermore, these findings should reassure physicians that starting insulin therapy in the more obese has no more risk of weight gain than in the less obese. Nevertheless, there is some weight gain in clinical practice with insulin therapy, although it appears that lifestyle measures can minimize weight gain in routine care (4). the integrity of the data and the accuracy of the data analysis.…”

Section: Discussionmentioning

confidence: 99%

Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin

et al. 2014

View full text Add to dashboard Cite

OBJECTIVEModerate weight gain is usual after starting insulin therapy. The identification and quantification of factors associated with weight gain may help target strategies for avoidance of weight gain. RESEARCH DESIGN AND METHODSThe noninterventional CREDIT (Cardiovascular Risk Evaluation in people with type 2 Diabetes on Insulin Therapy) study included data from people with type 2 diabetes starting any insulin in 314 centers, in 12 countries. From a number of predefined candidate explanatory variables, analyses identified factors associated with weight gain 1 year after starting insulin treatment, after adjusting for investigational site as a random factor. A multivariable backward regression analysis selected a subset of these factors associated with weight gain. RESULTSWe studied the 2,179 people with data for body weight change at 1 year and for potential predictive factors. The mean weight gain was 1.78 kg, and 24% gained ‡5.0 kg. Baseline factors associated with weight gain were BMI, A1C, insulin regimen, insulin dose, other glucose-lowering therapies, and hypertension; at 1 year, additional factors were A1C, insulin regimen, insulin dose, and use of other glucose-lowering therapies. In multivariable analysis, weight gain at 1 year was associated with a higher A1C at baseline, a higher insulin dose at baseline and at 1 year, and a lower baseline BMI. CONCLUSIONSBy the time insulin was started, a high baseline A1C and insulin dose requirements were independently associated with greater weight gain, as was lower baseline BMI. Insulin regimen per se was not a predictive factor.

show abstract

“…In einer Beobachtungsstudie kam es nach Beginn der Insulintherapie mit Insulinanaloga nur bei der intensivierten Insulintherapie zu einem signifikanten Anstieg der Hypoglykämien, nicht jedoch bei der BOT, supplementären oder konventionelle Insulintherapie [14]. Bei einer BOT ist in den ersten 12 Wochen lediglich bei einem von 500 Patienten mit einer schweren Hypoglykämie und bei einem von 50 Patienten mit einer symptomatischen Hypoglykämie zu rechnen [6].…”

Section: Einfluss Der Insulintherapie Auf Verschiedene Parameter ▼ Hyunclassified

Stellenwert der Insulinanaloga bei der Therapie von Menschen mit Typ-2-Diabetes

Gallwitz

Westrup

Schmeisl

2014

Dtsch med Wochenschr

View full text Add to dashboard Cite

An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study

Cited by 141 publications

References 27 publications

Practical Focus on American Diabetes Association/European Association for the Study of Diabetes Consensus Algorithm in Patients with Type 2 Diabetes Mellitus: Timely Insulin Initiation and Titration (Iran-AFECT)

Practical Focus on American Diabetes Association/European Association for the Study of Diabetes Consensus Algorithm in Patients with Type 2 Diabetes Mellitus: Timely Insulin Initiation and Titration (Iran-AFECT)

Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin

Stellenwert der Insulinanaloga bei der Therapie von Menschen mit Typ-2-Diabetes

Contact Info

Product

Resources

About